Investors
Invest in InDex
Pharmaceuticals
-
InDex Pharmaceuticals enrols first patient in the PK study with cobitolimod
December 8, 2021 Non Regulatory
-
InDex Pharmaceuticals enrols first patient in the phase III study CONCLUDE with cobitolimod in ulcerative colitis
November 24, 2021 Regulatory
InDex Pharmaceuticals Holding AB (publ) published its interim report Q3 for January-September 2021 on November 24, 2021 at 08:00 a.m. CET.
-
Deep dive presentation of the design of the phase III study CONCLUDE at HC Andersen Capital’s online event
-
Year-end Report 2021
-
Annual Report 2021
InDex Pharmaceuticals in numbers
-
15-30
The most common age of an ulcerative colitis diagnosis
-
2 Million
Patients living with ulcerative colitis in the US and Europe
-
6.3 billion USD
Total yearly sales of medications for ulcerative colitis
-
8 billion USD
The estimated total yearly sales of medication for ulcerative colitis in 2023
InDex Pharmaceuticals is developing cobitolimod for treatment of moderate to severe left-sided ulcerative colitis.
Investor contact
